Use of salmeterol with and without concurrent use of inhaled corticosteroids and the risk of asthma-related hospitalization among patients with asthma

Current Medical Research and Opinion

Volumn 24, Issue 3, 2008, Pages 859-867

  Wang, Meng Ting ^a   Skrepnek, Grant H ^b   Armstrong, Edward ^b   Sherrill, Duane L ^b,c   Harris, Robin B ^b   Tsai, Cheng Liang ^d   Malone, Daniel C ^b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Asthma; Drug safety; Hospitalization; Inhaled corticosteroids; Long acting beta agonists; Salmeterol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE; METHYLXANTHINE; SALMETEROL; STABILIZING AGENT; THEOPHYLLINE;

ADULT; ASTHMA; CASE CONTROL STUDY; COHORT ANALYSIS; CONFERENCE PAPER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DISEASE SEVERITY; DRUG USE; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; OUTPATIENT; RISK; RISK REDUCTION; SAMPLE SIZE; SEX;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; AGED; AGED, 80 AND OVER; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; CASE-CONTROL STUDIES; DATABASES AS TOPIC; DRUG THERAPY, COMBINATION; DRUG TOXICITY; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 41149134423     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X273020     Document Type: Conference Paper

References (37)

1. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics - 2002. J Allergy Clin Immunol 2002;110:S141-S219
2. Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid [Allen & Hanburys Limited UK Study Group]. Lancet 1994;344:219-24
3. Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481-8
4. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. New Engl J Med 1997;337:1405-11
5. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164:1392-7
6. Masoli M, Weatherall M, Holt S, et al. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 2005;60:730-4
7. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). Br Med J 2000;320:1368-73
8. Sin DD, Man J, Sharpe H, et al. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. J Am Med Assoc 2004;292:367-76
9. Greenstone IR, Ni Chroinin MN, Masse V, et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev 2005:CD005533
10. Ni Chroinin M, Greenstone IR, Danish A, et al. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev 2006:CD005535
11. Anderson HR, Ayres JG, Sturdy PM, et al. Bronchodilator treatment and deaths from asthma: case-control study. Br Med J 2005;330:117-23
12. Sears MR, Nelson HS, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial. Chest 2006;129:928-9
13. Martinez FD. Safety of long-acting beta-agonists - an urgent need to clear the air. New Engl J Med 2005;353:2637-9
14. Lanes SF, Lanza LL, Wentworth 3rd CE. Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol. Am J Respir Crit Care Med 1998;158:857-61
15. Mann RD, Kubota K, Pearce G, et al. Salmeterol: a study by prescription-event monitoring in a UK cohort of 15 407 patients. J Clin Epidemiol 1996;49:247-50
16. Williams C, Crossland L, Finnerty J, et al. Case-control study of salmeterol and near-fatal attacks of astirma. Thorax 1998;53:7-13
17. Lanes SF, Garcia Rodriguez LA, Huerta C. Respiratory medications and risk of asthma death. Thorax 2002;57:683-6
18. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26
19. Salpeter SR, Buckley NS, Ormiston TM, et al. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006;144:904-12
20. Ernst P, McIvor A, Ducharme FM, et al. Safety and effectiveness of long-acting inhaled (beta)-agonist bronchodilators when taken with inhaled corticosteroids. Ann Intern Med 2006;145:692-4
21. Lang DM. The controversy over long-acting beta agonists: examining the evidence. Cleve Clin J Med 2006;73:973-92
22. Suissa S, Ernst P, Bovin JF. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994;149:604-10
23. Rea HH, Scragg R, Jackson R. A case-control study of deaths from asthma. Thorax 1986;41:833-9
24. Suissa S, Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol 2001;107:937-44
25. Orsini L, Limpa-Amara S, Crown WH, et al. Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast. Ann Allergy Asthma Immunol 2004;92:523-9
26. Richardson D. An incidence density sampling program for nested case-control analyses. Occup Environ Med 2004;61:e59
27. Mitchell EA, Bland JM, Thompson JM. Risk factors for readmission to hospital for asthma in childhood. Thorax 1994;49:33-6
28. Clark DO, Von Korff M, Saunders K et al. A chronic disease score with empirically derived weights. Med Care 1995;33:783-95
29. Senthilselvan A, Lawson JA, Rennie DC, et al. Regular use of corticosteroids and low use of short-acting β2-agonists can reduce asthma hospitalization. Chest 2005;127:1242-51
30. Shireman TI, Heaton PC, Gay WE, et al. Relationship between asthma drug therapy patterns and healthcare utilization. Ann Pharmacother 2002;36:557-64
31. Koopmans JG, Lutter R, Jansen HM, et al. Adding salmeterol to an inhaled corticosteroid: long term effects on bronchial inflammation in asthma. Thorax 2006;61:306-12
32. Koopmans JG, Lutter R, Jansen HM, et al. Adding salmeterol to an inhaled corticosteroid reduces allergen-induced serum IL-5 and peripheral blood eosinophils. J Allergy Clin Immunol 2005;116:1007-13
33. Currie GP, Lee DK, Lipworth BJ. Long-acting beta2-agonists in asthma: not so SMART? Drug Saf 2006;29:647-56
34. Bensch G, Berger WE, Blokhin BM, et al. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann Allergy Asthma Immunol 2002;89:180-9
35. D'Urzo AD, Chapman KR, Cartier A, et al. Effectiveness and safety of salmeterol in nonspecialist practice settings. Chest 2001;119:714-9
36. 2-agonists for the treatment of asthma in Quebec: a population-based utilization review. Chest 2001;119:1316-21
37. Sturdy PM, Butland BK, Anderson HR, et al. Deaths certified as asthma and use of medical services: a national case-control study. Thorax 2005;60:909-15